Alzheimer disease: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• APOE 16
• MAPT 2
• APP 1
• NRF2 0
• NLRP3 0
• TREM2 0
• AKT 0
• BDNF 0
• TDP-43 2
• PI3K 0
• BACE1 0
• MAPK 0
• PPAR 0
• GLP-1 1
• AMPK 0
• mTOR 0
• PSEN1 1
• ERK 0
• STING 0
• NMDA 1
• SNCA 0
• TLR4 0
• JNK 0
• SIRT1 0
• CTNNB1 0
• STAT3 0
• TP53 0
• TNF 0
• HDAC 0
• HIF-1 0
• HMGB1 0
• SGLT2 0
• GPX4 0
• IL-1 0
• PCSK9 0
• COX-2 0
• HSP90 1
• C9orf72 0
• DPP-4 0
• PINK1 0
• IL-17 0
• TFEB 0
• IL-6 0
• PD-L1 0
• VEGF 0
• YAP 0
• AQP4 0
• CD33 0
• IGF1R 0
• MMP-9 0
• CCR5 0
• EGFR 0
• FTO 0
• GBA1 0
• GIP 0
• JAK 0
• KEAP1 0
• PARP 0
• PD-1 0
• ACE2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 15,599 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Adaptation and Normalization of a Verbal Episodic Memory Test in French Sign Language

  NCT06902753· Poitiers University Hospital· Updated 27 Oct 2026

  “Inclusions suspended during the period between phase 1 (adaptation of the test in French sign Language) and phase 2 (inclusion for the standardization of the test).”Registry text, quoted unchanged. Source

• Terminated

  Presence of Anti-RACH Antibodies and Neurocognitive Disorder in Myasthenic or Alzheimers's Patients.

  NCT06523296· Centre Hospitalier Universitaire de Nice· Updated 23 Oct 2026

  “recruitment challenges”Registry text, quoted unchanged. Source

• Terminated

  Home-based tDCS in Frontotemporal Dementia or Alzheimer's Disease

  NCT05978804· Johns Hopkins University· Updated 21 Oct 2026

  “Lack of funding”Registry text, quoted unchanged. Source

• Withdrawn

  GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

  NCT07677865· West China Hospital· Updated 16 Oct 2026

  “poor accrual and funding issues”Registry text, quoted unchanged. Source

• Suspended

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Updated 21 Sept 2026

  “Administrative”Registry text, quoted unchanged. Source

• Withdrawn

  DECIDE: Dyads and Families

  NCT05139290· Emory University· Updated 18 Sept 2026

  “No participants were enrolled in the clinical trial portion. The community-engaged nature of the project required more time than anticipated, and funding was insufficient to support the implementation of the proposed intervention.”Registry text, quoted unchanged. Source

• Withdrawn

  Implementation of AIP Services for Older Adults With AD

  NCT07361601· Northwestern University· Updated 14 Sept 2026

  “Not a clinical trial so retiring ClinicalTrials.gov record”Registry text, quoted unchanged. Source

• Terminated

  The Ketogenic Diet for Alzheimer's Disease

  NCT04701957· Assistance Publique - Hôpitaux de Paris· Updated 10 Sept 2026

  “lake of inclusions”Registry text, quoted unchanged. Source

• Withdrawn

  REVERSE-Long COVID-19 With Baricitinib Study

  NCT05858515· Vanderbilt University Medical Center· Updated 9 Sept 2026

  “This submission for the pilot study has been withdrawn as the full trial opened under a different NCT number before participants enrolled in the pilot.”Registry text, quoted unchanged. Source

• Terminated

  Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

  NCT05267535· Neurim Pharmaceuticals Ltd.· Updated 9 Sept 2026

  “Treatment with 20 mg piromelatine did not demonstrate efficacy over treatment with placebo based on analysis with the ADAS-Cog 14 subscale and with other cognitive and neuropsychiatric parameters.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

  NCT07011732· Bristol-Myers Squibb· Source

• A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

  NCT07688213· Sanofi· Source

• Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease

  NCT07779863· The University of Hong Kong· Source

• A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

  NCT06402838· Hoffmann-La Roche· Source

• InRAD Observational Study

  NCT07213700· Stichting International Registry for Alzheimer's Disease and other Dementias Foundation· Source

• Locus-coeruleus Function in Normal Elderly and AD Risk

  NCT04403165· NYU Langone Health· Source

• PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

  NCT07169630· National Institute of Mental Health (NIMH)· Source

• A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

  NCT07717411· Hoffmann-La Roche· Source

• Nabilone for Agitation Blinded Intervention Trial

  NCT04516057· Sunnybrook Health Sciences Centre· Source

• Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

  NCT07781657· Hoffmann-La Roche· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 84
• Organoids 36
• Mendelian Randomization Analysis 136
• CRISPR-Cas Systems 24
• Gene Expression Profiling 174
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 17
• Exome Sequencing 7
• Proteomics 226
• Metabolomics 81
• Mass Spectrometry 62
• Flow Cytometry 16
• Immunohistochemistry 74
• Liquid Biopsy 5
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 669
• Magnetic Resonance Imaging 991
• Machine Learning 251
• Deep Learning 166
• Cohort Studies 533
• Genome-Wide Association Study 213

• Brain Region-Specific Peptide and Proteomic Signatures Inform Alzheimer's Disease Biomarker Panels.

  J Proteome Res, Nov 2026

• Super-Cross-Reactive Recognition Enables Preclinical Diagnosis of Alzheimer's Disease.

  J Am Chem Soc, Oct 2026

• Explainable machine learning for identifying high-risk Alzheimer's disease and key health characteristics among community-dwelling adults.

  Front Public Health, Oct 2026

• Single-cell, spatial, and machine learning analyses identify ANKIB1 as an oligodendrocyte-anchored palmitoylation-associated candidate biomarker of Alzheimer's disease.

  Transl Psychiatry, Oct 2026

• Advances in artificial intelligence-driven MRI research in Alzheimer's disease.

  Front Neurol, Oct 2026

• A model of brain function to predict tau across Alzheimer's disease and related disorders.

  Nat Commun, Oct 2026

• The application progress of artificial intelligence in the diagnosis of Alzheimer's disease.

  Front Neurol, Oct 2026

• EEG-based brain effective and functional connectivity predict PET-defined amyloid positivity in cognitively normal individuals.

  Alzheimers Dement, Oct 2026

• Machine Learning in Dementia Research: Trends, Biomarkers, Prediction Goals, and Data Modalities.

  Brain Behav, Oct 2026

• Integration of neuroimaging signatures of aging and Alzheimer's with fluid biomarkers.

  Alzheimers Dement, Oct 2026

See which targets of this disease your abstract mentions, and go to the people working on them.